Surveying the hypercholesterolemia landscape
This article was originally published in Scrip
Executive Summary
The two lipid lowerers under scrutiny at the FDA this week each use a novel strategy to reduce cholesterol levels, but what other approaches for hypercholesterolemia/dyslipidemia are in the pipeline?